In an exploratory analysis, based on tumor biomarkers, the efficacy was better in patients who had no ESR1 mutation (ESR1 wild type); median PFS for the ESR1-WT treated with ribociclib was 8.3 months, compared to 2.7 months for those on placebo. This evidence concerns the gene ESR1 and neoplasm.